214 related articles for article (PubMed ID: 26777258)
1. Retrospective comparison of voglibose or acarbose as an add-on therapy to sulfonylureas in Western Indian patients with uncontrolled overweight/obese type 2 diabetes.
Talaviya PA; Saboo BD; Dodiya HG; Rao SK; Joshi SR; Modh VB; Ghadiya SV
Diabetes Metab Syndr; 2016; 10(2):88-91. PubMed ID: 26777258
[TBL] [Abstract][Full Text] [Related]
2. Comparison of acarbose and voglibose in diabetes patients who are inadequately controlled with basal insulin treatment: randomized, parallel, open-label, active-controlled study.
Lee MY; Choi DS; Lee MK; Lee HW; Park TS; Kim DM; Chung CH; Kim DK; Kim IJ; Jang HC; Park YS; Kwon HS; Lee SH; Shin HK
J Korean Med Sci; 2014 Jan; 29(1):90-7. PubMed ID: 24431911
[TBL] [Abstract][Full Text] [Related]
3. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients.
Vichayanrat A; Ploybutr S; Tunlakit M; Watanakejorn P
Diabetes Res Clin Pract; 2002 Feb; 55(2):99-103. PubMed ID: 11796175
[TBL] [Abstract][Full Text] [Related]
5. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.
Derosa G; Mereu R; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Palumbo I; Maffioli P; Randazzo S; Cicero AF
J Clin Pharm Ther; 2010 Oct; 35(5):565-79. PubMed ID: 20831680
[TBL] [Abstract][Full Text] [Related]
6. Different clinical prognostic factors are associated with improved glycaemic control: findings from MARCH randomized trial.
Han J; Yu H; Tu Y; Pang J; Liu F; Bao Y; Yang W; Jia W
Diabet Med; 2017 Apr; 34(4):490-499. PubMed ID: 27151271
[TBL] [Abstract][Full Text] [Related]
7. Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obesity.
Sun W; Zeng C; Liao L; Chen J; Wang Y
Curr Med Res Opin; 2016 Aug; 32(8):1389-96. PubMed ID: 27052634
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of acarbose and metformin in newly diagnosed type 2 diabetes patients stratified by HbA1c levels.
Zhang JP; Wang N; Xing XY; Yang ZJ; Wang X; Yang WY
J Diabetes; 2016 Jul; 8(4):559-67. PubMed ID: 26331290
[TBL] [Abstract][Full Text] [Related]
9. Renal Outcomes of Pioglitazone Compared with Acarbose in Diabetic Patients: A Randomized Controlled Study.
Chen YH; Tarng DC; Chen HS
PLoS One; 2016; 11(11):e0165750. PubMed ID: 27812149
[TBL] [Abstract][Full Text] [Related]
10. Glycemic excursions are positively associated with HbA1c reduction from baseline after treatment with acarbose in patients with type 2 diabetes on metformin monotherapy.
Wang JS; Lee IT; Lee WJ; Lin SD; Su SL; Tu ST; Tseng YH; Lin SY; Sheu WH
J Diabetes; 2017 Mar; 9(3):248-255. PubMed ID: 27043224
[TBL] [Abstract][Full Text] [Related]
11. Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients.
Matsumura M; Monden T; Miyashita Y; Kawagoe Y; Shimizu H; Nakatani Y; Domeki N; Yanagi K; Ikeda S; Kasai K
Adv Ther; 2009 Jun; 26(6):660-6. PubMed ID: 19568704
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Benefits of Acarbose vs Sulfonylureas in Patients With Type 2 Diabetes Treated With Metformin.
Hsu PF; Sung SH; Cheng HM; Shin SJ; Lin KD; Chong K; Yen FS; Yu BH; Huang CT; Hsu CC
J Clin Endocrinol Metab; 2018 Oct; 103(10):3611-3619. PubMed ID: 30113697
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas.
Lin BJ; Wu HP; Huang HS; Juang JH; Sison A; bin Abdul Kadir DK; Cho CG; Sridama W;
J Diabetes Complications; 2003; 17(4):179-85. PubMed ID: 12810240
[TBL] [Abstract][Full Text] [Related]
14. Acarbose reduces body weight irrespective of glycemic control in patients with diabetes: results of a worldwide, non-interventional, observational study data pool.
Schnell O; Weng J; Sheu WH; Watada H; Kalra S; Soegondo S; Yamamoto N; Rathod R; Zhang C; Grzeszczak W
J Diabetes Complications; 2016; 30(4):628-37. PubMed ID: 26935335
[TBL] [Abstract][Full Text] [Related]
15. Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial.
Yang W; Liu J; Shan Z; Tian H; Zhou Z; Ji Q; Weng J; Jia W; Lu J; Liu J; Xu Y; Yang Z; Chen W
Lancet Diabetes Endocrinol; 2014 Jan; 2(1):46-55. PubMed ID: 24622668
[TBL] [Abstract][Full Text] [Related]
16. The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data.
Lin SD; Wang JS; Hsu SR; Sheu WH; Tu ST; Lee IT; Su SL; Lin SY; Wang SY; Hsieh MC
J Diabetes Complications; 2011; 25(5):332-8. PubMed ID: 21813293
[TBL] [Abstract][Full Text] [Related]
17. MARCH2: comparative assessment of therapeutic effects of acarbose and metformin in newly diagnosed type 2 diabetes patients.
Wang G; Liu J; Yang N; Gao X; Fan H; Xu Y; Yang W
PLoS One; 2014; 9(8):e105698. PubMed ID: 25148570
[TBL] [Abstract][Full Text] [Related]
18. The effect of voglibose on metabolic profiles in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of clinical trials.
Nowrouzi-Sohrabi P; Tabrizi R; Rezaei S; Jafari F; Hessami K; Abedi M; Jalali M; Keshavarzi P; Shahabi S; Kolahi AA; Carson-Chahhoud K; Sahebkar A; Safiri S
Pharmacol Res; 2020 Sep; 159():104988. PubMed ID: 32504833
[TBL] [Abstract][Full Text] [Related]
19. Alpha-glucosidase inhibitors for type 2 diabetes mellitus.
Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; Rutten GE; Van Weel C
Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD003639. PubMed ID: 15846673
[TBL] [Abstract][Full Text] [Related]
20. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
